
Mobile phone ownership is not a barrier to uptake of community-based ART and viral suppression

Alastair van Heerden¹, Ruanne V Barnabas², Stephen Asiimwe³, Deenan Pillay⁴, Maryam Shahmanesh⁴, Torin Schaafsma², Meighan Krows², Kombi Sausi¹, Nsika Sithole⁴, Bosco Turyamureeba³, Connie Celum², and Heidi van Rooyen¹ for the DO ART Study Team

Background

- Community-based delivery of antiretroviral therapy (ART) increases viral suppression and often requires tracking and tracing of clients living with HIV to coordinate care.
- Mobile phones are an effective method for communicating with clients and facilitates counseling and coordination of care.





LE17267-1-244

Research Question

Does the ownership of a mobile phone increase access to community-based ART and thus increase viral suppression?

Methods

- Delivery Optimization of Antiretroviral Therapy (DO ART) Study in South Africa and Uganda evaluated community-based delivery of ART compared to clinic-based care.
- During enrollment people living with HIV reported mobile phone ownership and provided their phone number.
- Care was coordinated using mobile phones, when one was available, but mobile phone ownership or access was not a requirement for study participation.
- At study exit (12 months) plasma HIV viral load was determined using the bioMérieux NucliSens assay.

Figure 1: Rate of secure mobile phone access, by participant characteristics

Figure 3. Examples of common phones used by participants Hisense U961, Samsung J7, Huawei Y3 LITE

- There was no significant association between age and mobile phone access (adjusting for gender).
- There was no significant association between mobile phone ownership and viral load suppression at study exit a(RR: 1.09, 95% CI: 0.98 – 1.21, p = 0.11), adjusting for age and gender.

Table 2: Relative risk (RR) of suppressed viral load at exit

	RR (Confidence interval)	p	
Has Mobile Phone Access	1.08 (0.98-1.21)	0.12	
Gender Female	1.10 (1.03-1.19)	0.005	
Age category 30 – 49	0.96 (0.89-1.03)	0.24	
$\Lambda_{aa} = 10$	1 08 (0 06 1 21)	0 10	

These data were used to measure the prevalence of mobile phone ownership and to calculate relative risks of ownership and HIV treatment outcomes using a modified Poisson regression for binary outcomes with robust standard errors, adjusting for within household correlation.

Results

- Of 1,531 participants, most (84%) owned a mobile phone.
- Women were 9% more likely to have access to a mobile phone than men when controlling for age (95% CI: 4 - 14).

Table 1: Rate of secure mobile phone access, by participant <u>characteristics</u>

	Characteristics	n / N	percent
Gender	Male	569/706	(81%)
	Female	720/823	(87%)
Age category	18 - 29	462/550	(84%)
	30 - 49	732/857	(85%)
	> 49	95/122	(78%)
Exit viral load	Detectable	363/443	(82%)
	Suppressed	870/1014	(86%)
	Unknown	56/72	(78%)

Age category > 49

Discussion

- Mobile phone ownership is now almost ubiquitous, although smart phone uptake is still slower in study communities.
- We found no association between viral suppression and mobile phone ownership in the context of high rates of mobile phone ownership in a community-based ART project in South Africa.
- Owning a mobile phone may not be a requirement to access community-based ART delivery programs and realize the health benefits of decentralized services.
- Given that more women than men had mobile phones, mHealth programs requiring access to a mobile phone may unintentionally exclude men.

Conclusion

Mobile phone ownership was not associated with viral suppression in a community-based ART project in South Africa.

Funding & Acknowledgements

Bill and Melinda Gates Foundation The men and women who made this work possible.

Affiliations

. Human Sciences Research Council, Sweetwaters, KwaZulu-Natal, South Africa, 2. University of Nashington, Seattle, WA, 3. Integrated Community-Based Initiatives, Kabwohe, Uganda, 4. Africa Health Research Institute, KwaZulu-Natal, South Africa, 5. Centre for Health Economics, University of York, UK

PRESENTED AT IAS 2021 – the 11th **IAS Conference on HIV Science** 18-21 JULY 2021









Delivery Optimization for Antiretroviral Therapy